Comerica Bank Purchases Shares of 58,040 RAPT Therapeutics, Inc. (NASDAQ:RAPT)

Comerica Bank bought a new position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 58,040 shares of the company’s stock, valued at approximately $92,000. Comerica Bank owned approximately 0.17% of RAPT Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Picton Mahoney Asset Management boosted its holdings in RAPT Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after purchasing an additional 14,697 shares in the last quarter. Los Angeles Capital Management LLC increased its holdings in shares of RAPT Therapeutics by 9.2% during the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock worth $348,000 after buying an additional 18,558 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of RAPT Therapeutics by 298.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock worth $34,000 after buying an additional 25,130 shares during the last quarter. Barclays PLC boosted its position in RAPT Therapeutics by 277.2% during the 3rd quarter. Barclays PLC now owns 39,729 shares of the company’s stock worth $79,000 after purchasing an additional 29,195 shares during the period. Finally, Geode Capital Management LLC boosted its position in RAPT Therapeutics by 4.9% during the 4th quarter. Geode Capital Management LLC now owns 716,937 shares of the company’s stock worth $1,133,000 after purchasing an additional 33,758 shares during the period. Hedge funds and other institutional investors own 99.09% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of RAPT Therapeutics in a research note on Monday, March 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $4.00.

RAPT Therapeutics Stock Up 3.7%

Shares of NASDAQ:RAPT opened at $0.84 on Monday. The firm has a fifty day moving average of $1.00 and a two-hundred day moving average of $1.21. The firm has a market capitalization of $110.92 million, a P/E ratio of -0.30 and a beta of -0.04. RAPT Therapeutics, Inc. has a 12-month low of $0.71 and a 12-month high of $4.83.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.23. Equities research analysts expect that RAPT Therapeutics, Inc. will post -2.14 earnings per share for the current fiscal year.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.